Drug intelligence / Profile preview

BRI-101

Development stage: Preclinical
Lead developer: BRI Pharma
Modality: Small Molecules

Overview

BRI-101 is a small molecule inhibitor of fatty acid-binding protein 3 (FABP3) being developed by BRI Pharma for the treatment of Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). FABP3 is involved in the uptake and pathological aggregation of α-synuclein in dopaminergic neurons, which is a key hallmark of synucleinopathies. By inhibiting FABP3, BRI-101 aims to prevent the accumulation of α-synuclein and slow disease progression. The compound has demonstrated good brain penetration and a wide safety margin in preclinical studies.

Targets

FABP3 (Fatty acid-binding protein 3)

Beyond the preview

Go deeper on BRI-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRI-101.

Explore the full profile